When tissue is not the only issue: Poorly differentiated lung squamous-cell carcinoma with adrenal, costochondral, and cardiac metastases – case report

Nonmelanoma skin cancer is the most common cancer in the world, and lung cancer is the leading cause of death from cancer. Histologically, squamous cell carcinoma (SCC) is the second most prevalent type of both skin and lung cancers. We report the case of a 38-year-old female with metastatic, poorly differentiated lung SCC detected on chest X-ray after she presented to the hospital with cough and dyspnea. She had had a 7.5 cm moderately differentiated well-circumscribed posterior scalp SCC completely excised eight years earlier. CT scan showed a large right lung mass, nodular filling defect in the left atrium (LA), and metastases to the adrenal glands and the first rib. Her pulmonary tumor extends to the LA via the right superior pulmonary vein, which is rarely reported in the literature. Ultrasound-guided biopsy of the rib mass showed poorly differentiated SCC. The patient received urgent radiotherapy, given superior vena cava and mainstem bronchus compression. Head CT showed no brain metastasis. A biopsy of the left adrenal initially reported an undifferentiated pleomorphic sarcoma; however, a second pathologist reported it as a poorly differentiated carcinoma of lung origin. At least three pathologists verified the specimen, and it had a PD-L1 test with a 1-49% score. An initial echocardiogram confirmed the LA mass. The patient received a Paclitaxel-Carboplatin-Pembrolizumab regimen as the first-line treatment for metastatic SCC. A repeat echocardiogram after cycle 1 showed a decrease in the size of the tumor in the LA. Almost five months after her initial visit, this young woman’s symptoms and performance status have improved post-palliative radiotherapy and chemo-immunotherapy. Follow-up CT showed smaller lung, nodal, adrenal, and costochondral masses, and evidence of necrosis. This case is clinically relevant because it represents a common problem presenting uncommonly. Moreover, it highlights that ultrasound-guided interventions and medical imaging are essential in directing metastatic cancer diagnosis, treatment, and follow-up, especially when pathology cannot confirm but only presume a specific diagnosis.

[1]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[2]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  H. Frick,et al.  Multiple primary tumours: challenges and approaches, a review , 2017, ESMO Open.

[4]  P. Rosenberg,et al.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohort , 2016, Cancer.

[5]  D. Takai,et al.  Differential diagnosis between primary lung squamous cell carcinoma and pulmonary metastasis of head and neck squamous cell carcinoma , 2016, Expert review of anticancer therapy.

[6]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  C. Bonaïti‐pellié,et al.  Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. McLoone,et al.  Second primary cancer risk - the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study , 2014, BMC Cancer.

[9]  R. Zlotecki,et al.  Multidisciplinary Management of Soft Tissue Sarcoma , 2013, TheScientificWorldJournal.

[10]  Jonathon M. Firnhaber Diagnosis and treatment of Basal cell and squamous cell carcinoma. , 2012, American family physician.

[11]  F. Stella,et al.  Surgical results and long-term follow-up of T(4)-non-small cell lung cancer invading the left atrium or the intrapericardial base of the pulmonary veins. , 2012, Interactive cardiovascular and thoracic surgery.

[12]  D. Margolis,et al.  Delayed treatment and continued growth of nonmelanoma skin cancer. , 2011, Journal of the American Academy of Dermatology.

[13]  G. Hospers,et al.  Retrospective Denial as A Coping Method , 2011, Journal of Clinical Psychology in Medical Settings.

[14]  L. Kemény,et al.  Neglected Basal Cell Carcinomas in the 21st Century , 2010, Journal of skin cancer.

[15]  D. Malkin Li-fraumeni syndrome. , 2001, Genes & cancer.

[16]  B. Grand,et al.  Lung cancer invading the pericardium: quantum of lymph nodes. , 2010, The Annals of thoracic surgery.

[17]  J. de Haes,et al.  Denial in cancer patients, an explorative review , 2007, Psycho-oncology.

[18]  B. Diffey,et al.  Skin cancer incidence and the ageing population , 2005, The British journal of dermatology.

[19]  S. Markakidis,et al.  Large bilateral adrenal metastases in non-small cell lung cancer , 2004, World journal of surgical oncology.

[20]  G. Heppner,et al.  Tumor heterogeneity: biological implications and therapeutic consequences , 2004, Cancer and Metastasis Reviews.

[21]  T. Aburano,et al.  Pulmonary Vein and Left Atrial Invasion by Lung Cancer: Assessment by Breath-Hold Gadolinium-Enhanced Three-Dimensional MR Angiography , 2000, Journal of computer assisted tomography.

[22]  N. Suzuki,et al.  Heterogeneity and variability of artificial lung colony-forming ability among clones from mouse fibrosarcoma. , 1978, Cancer research.

[23]  T. Hackett,et al.  Development of a quantitative rating scale to assess denial. , 1974, Journal of psychosomatic research.

[24]  C. Pasternak,et al.  STRUCTURAL ALTERATIONS IN THE SURFACE MEMBRANE DURING THE CELL CYCLE , 1971, The Journal of cell biology.